Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration

Shiri Guy-Alfandary, Sasha Zhurat, Maya Berlin, Tal De Haan, Itai Gueta, Renata Shihmanter, Ahuva Golik, Matitiahu Berkovitch, Sara Eyal, Lee H. Goldstein*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations
Original languageAmerican English
Pages (from-to)1156-1158
Number of pages3
JournalClinical Pharmacology and Therapeutics
Issue number6
StatePublished - Dec 2022

Bibliographical note

Funding Information:
This perspective received no funding. The authors acknowledge the helpful input of Mg. Hadas Rotem, M. Sc., and Dr. Einat Gorelik, Pharm.D., from the Israeli MOH.

Cite this